Drug intelligence / Profile preview

KP102

Development stage: Unknown
Lead developer: Kaken Pharmaceutical
Modality: Small Molecules
Administration: Intravenous, Subcutaneous, Implant

Overview

KP102 is an early-stage therapeutic candidate currently in the discovery phase for the treatment of Alzheimer's dementia. Developed by the South Korean pharmaceutical company Korea Pharma, the asset is part of a research pipeline focused on central nervous system (CNS) disorders. While it is listed in the company's official R&D pipeline, specific details regarding its molecular target, mechanism of action, and chemical composition have not been disclosed to the public. It represents one of several programs Korea Pharma is pursuing in the neurodegeneration space, alongside other candidates like EPPS and Osmotin.

Brand names: GHRP-2GHRP2GHRP 2Pralmorelin Hydrochloride
Other names: growth hormone-releasing peptide 2pralmorelinGHRP2GHRP-2GHRP 2

Targets

GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on KP102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP102.

Explore the full profile